Showing the latest 10 filings. Sign in to filter or browse the full history.
10 of 133 filings·Updated 28 Sept 2026
Showing 10 of 133 filings.
28 Sept 20261 filing
Board Meeting

MedPlus Board to consider unaudited standalone and consolidated results for quarter and half-year ended Sept 30, 2026

Meeting Details

  • Board meeting scheduled for Oct 27, 2026; time and venue not disclosed.

Key Agenda Items

  • Consider and approve unaudited standalone and consolidated results for quarter and half-year ended Sept 30, 2026.

Other Notes

  • Trading window closed from Oct 01, 2026 until 48 hours after the unaudited results declaration.
Filed 15:20View Source
10 Sept 20262 filings
Company UpdateGeneral

MedPlus notes SEBI LODR non-compliance; AGM-approved NED appointment; fine levied

Regulatory non-compliance update

  • Non-compliance under SEBI LODR 17(1A) due to appointment of 75-year-old NED Ajit Rangnekar.
  • AGM held 17 August 2026 approved the appointment via special resolution.
  • Exchanges levied a fine; company to strengthen governance systems to prevent recurrence.
  • Non-compliance attributed to bona fide interpretational difference, not willful default.
  • Board directed management to strengthen governance compliance and processes.
  • Board submitted comments to Exchanges for information.
Filed 16:12View Source
Board MeetingOutcome of Board Meeting

MedPlus Board approves acquisition of remaining 0.01% stake in Optival to become wholly owned

Acquisition of Optival residual stake

  • Cash consideration Rs 1.10 crore for 17,986 Optival Health Solutions Private Limited shares.
  • Acquisition increases MedPlus stake from 99.99% to 100%, making Optival a wholly owned subsidiary.
  • Not a related party transaction; existing Optival shareholders are not related to MedPlus or promoter group.
  • Completion subject to requisite documentation and dematerialization/transmission formalities.
  • Expected to complete at the earliest possible date.
Filed 13:21View Source
21 Aug 20262 filings
Insider Trading / SASTDisclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011

Medplus Health Services Ltd filing under Reg. 29(1) mentions Catalyst Trusteeship Limited

Filing fragment details

  • Issuer: Medplus Health Services Ltd (543427).
  • Counterparty/related entity: Catalyst Trusteeship Limited.
Filed 18:05View Source
Insider Trading / SASTDisclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

ICICI Prudential Mutual Fund raises Medplus stake to 7.18% via open-market purchase

Acquisition details

  • Target: Medplus Health Services Ltd; acquirer: ICICI Prudential Mutual Fund (not promoter).
  • Pre-transaction holding: 60,94,338 voting shares (5.07%), encumbrances none.
  • Acquired: 25,29,352 voting shares (2.11%); open market; Aug 20, 2026.
  • Post-transaction holding: 86,23,690 voting shares (7.18%).
  • Period of net acquisition: July 23, 2026 to August 20, 2026.
  • Equity share capital before/after: ₹24,02,74,122; voting rights: 12,01,37,061 shares.
  • Total diluted capital after: 12,02,37,751 shares (₹24,04,75,502).
Filed 16:20View Source
18 Aug 20261 filing
AGM/EGMAGM

MedPlus Health Services' 20th AGM held via video conferencing; all six resolutions approved.

AGM Details

  • Held on Aug 17, 2026 via video conferencing / other audio-visual means.
  • Remote e-voting and on-site e-voting occurred; Scrutinizer's Report dated Aug 18, 2026 attached.
  • Six resolutions were placed before members and approved with requisite majority.

Key Resolutions & Voting

  • Resolution 1 approved by Members with requisite majority.
  • Resolution 2 approved by Members with requisite majority.
  • Resolution 3 approved by Members with requisite majority.
  • Resolution 4 approved by Members with requisite majority.
  • Resolution 5 approved by Members with requisite majority.
  • Resolution 6 approved by Members with requisite majority.
Filed 19:15View Source
17 Aug 20261 filing
AGM/EGMAGM

MedPlus Health Services holds VC/OAVM AGM; independent directors appointed, MD/CEO re-appointed, and cost auditor remuneration ratified

AGM details

  • Date/time disclosed; mode: VC/OAVM.
  • Venue deemed at registered office.
  • Quorum confirmed; meeting conducted via VC/OAVM.

Key resolutions

  • Ordinary: Adopt standalone and consolidated financial statements for FY 2025-26; outcome pending.
  • Ordinary: Re-appoint Director retiring by rotation; outcome pending.
  • Special: Appoint Independent Director; outcome pending.
  • Special: Appoint another Independent Director; outcome pending.
  • Ordinary: Re-appoint Managing Director & CEO; outcome pending.
  • Ordinary: Ratify remuneration to Cost Auditors for FY 2026-27; outcome pending.

Governance changes

  • Two Independent Directors appointed (non-executive roles).
  • MD & CEO re-appointed; leadership term details not disclosed here.

Auditors & related matters

  • Statutory auditors delivered unqualified opinions on FY 2025-26 financials.
  • Remuneration of Cost Auditors for FY 2026-27 ratified.

Voting status

  • Consolidated voting results pending; Scrutinizer's report to be uploaded to exchanges.
Filed 19:18View Source
6 Aug 20261 filing
Company UpdateGeneral

Optival Health Solutions subsidiary reports three one-day drug license suspensions in Karnataka

Regulatory update: Karnataka drug license suspensions

  • Optival Health Solutions (MedPlus subsidiary) reports three one-day suspensions under Drug and Cosmetics Act Rule 65.
  • Store 1: Ashram Road, Vijayapura; order received 05-Aug-2026; potential revenue loss ₹0.24 lakh.
  • Store 2: Sindagi, Karnataka; order received 05-Aug-2026; potential revenue loss ₹0.17 lakh.
  • Store 3: Hanuman Talkies Road, Raichur; order received 05-Aug-2026; potential revenue loss ₹0.23 lakh.
Filed 18:03View Source
31 Jul 20261 filing
Company UpdateGeneral

Telangana store drug license suspension; potential revenue impact Rs 2.34 lacs

Telangana store drug license suspension

  • Subsidiary Optival Health Solutions: five-day suspension of Telangana store's drug license.
  • Order received 30 July 2026 from Assistant Director, Drugs Control Administration, Warangal.
  • Potential revenue loss of Rs 2.34 lacs.
Filed 17:49View Source
28 Jul 20261 filing
Insider Trading / SASTDisclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

Catalyst Trusteeship creates pledge over 49 lakh MedPlus shares; encumbrance rises to 2.075 crore.

Parties and Transaction Overview

  • Target: MedPlus Health Services Limited; acquirer: Catalyst Trusteeship Limited (not promoter group).
  • Mode: Creation of pledge over MedPlus shares; date: 24 June 2026.
  • Acquirer not part of promoter/promoter group.

Holding and Capital Context

  • Pre-transaction encumbrance: 1,58,50,400 shares (13.19%); diluted 13.18%.
  • Post-transaction encumbrance: 2,07,50,400 shares (17.27%); diluted 17.26%.
  • Shares pledged by acquirer: 49,00,000 (4.08%).
  • Equity share capital before/after: Rs 24,02,74,122.
  • Total diluted share capital after: Rs 24,04,75,502.
  • Total diluted voting capital after: 12,02,37,751 shares (17.26%).
Filed 15:36View Source
Showing 10 of 133 filings